Interv Akut Kardiol. 2007;6(3):97-101

Atrial fibrillation - new guidelines focused on cerebral embolism

Miroslava Laníková, Radek Pudil
I. interní klinika Fakultní nemocnice v Hradci Králové

The leading interest in recent years has been in risk stratification and prevention of thromboembolic complications in atrial fibrillation (AF) which, with its potential consequences, does definitely not belong to „innocent“ arrhythmias. Present guidelines for management of patients with atrial fibrillation focused on stroke, which is certainly a disabling complication of this rhythm disturbance. The precise mechanism predisposing to thrombus formation is unclear. However, we know that macroscopic, haemodynamic factors and also microscopic changes participate in its formation. An insignificant effort has also been made to identify risk factors, which would contribute to approaches in anticoagulation therapy. Despite an encouraging increase of antithrombotic therapy in the last couple of years, there are still a lot of patients who do not receive this treatment. One of the main tasks in the treatment of AF is to correctly identify high risk patients, whose gain from anticoagulation therapy is definite, and low risk patients who have not benefited from this treatment, on the contrary they are exposed to an unnecessary risk of bleeding. Just the higher focus on thrombotic complications and its prevention plays an important role in the decrease of incidence of these events in patients with AF.

Keywords: atrial fibrillation, anticoagulation therapy, stroke

Published: July 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Laníková M, Pudil R. Atrial fibrillation - new guidelines focused on cerebral embolism. Interv Akut Kardiol. 2007;6(3):97-101.
Download citation

References

  1. Fuster V, Ryden LE, Cannom DS et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation - executive summary. Eur Heart J. 2006; 27: 1976-2030. Go to original source... Go to PubMed...
  2. Čihák R, Heinc P. Doporučené postupy pro léčbu pacientů s fibrilací síní. Cor et Vasa. 2002; 46: K67-K77.
  3. Psaty BM, Manolio TA, Kuller LH, et al. Incidence of and risk factors for atrial fibrillation in older adults. Circualtion. 1997; 96: 2455-2461. Go to original source... Go to PubMed...
  4. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001; 2370-2375. Go to original source...
  5. Lukl J. Farmakologická léčba fibrilace síní. Remedia. 2004; 2: 126-130.
  6. Pedersen OD, Brendrop B. Prevalence, prognostic significance and treatment of atrial fibrillation in congestive heart failure with particular reference to the DIAMOND-CHF study. CHF. 2003; 9: 333-340. www. medscape. com/viewarticle/465717. Go to original source... Go to PubMed...
  7. Lip G, Godfredsen J. Cardiac arrhythmias a clinical approach. Edinburgh: Mosby. 2003; 4-133.
  8. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of anti thrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials [published erratum appears in Arch Intern Med 1994; 154: 2254]. Arch Intern Med. 1994; 154: 1449-1457. Go to original source...
  9. Stewart S, Hart CL, Hole DJ et al. A population-based study of the long-term risks associated with atrial fibrillation; 20-year follow-up of the Renfrew/Paisley study. Am J Med. 2002; 113: 359-364. Go to original source... Go to PubMed...
  10. Krahn AD, Manfreda J, Tate RB et al. The natural history of atrial fibrillation: incidence, risk factors and prognosis in the Manitoba Follow-up Study. Am J Med. 1995; 98: 476-484. Go to original source... Go to PubMed...
  11. Wolf PA, Abott RD, Kannel WB et al. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991; 22: 983-988. Go to original source... Go to PubMed...
  12. Wolf PA, Dawber TR, Thomas HE Jr et al. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke; the Framingham Study. Neurology. 1978; 28: 973-977. Go to original source... Go to PubMed...
  13. Halperin JL, Hart RG. Atrial fibrillation and stroke: new ideas, persisting dilemmas. Stroke. 1988; 19: 937-941. Go to original source... Go to PubMed...
  14. Bogousslavsky j, Van Melle G, Regli F et al. Pathogenesis of anterior circulation stroke in patients with nonvalvular atrial fibrillation: the Lausane Stroke Registry. Neurology. 1990; 40: 32-36. Go to original source... Go to PubMed...
  15. Miller VT, Rothrock JF, Pearce LA et al. Ischemic stroke in patients with atrial firbrillation: effect of aspirin according to stroke mechanism. Stroke prevention in Atrial Fibrillation Investigatiory. Neurology. 1993; 43 Go to original source... Go to PubMed...
  16. Kanter MC, Tegeler CH, Pearce LA et al. Carotide stenosis in patients with atrila fibrillation. Prevalence, risk factors, and relationship to stroke in the Stroke Prevention in Atrial Fibrillation Study. Arch Inter Med. 1994; 154: 1372-1377. Go to original source...
  17. Hart RG, Halperin JL. Atrila fibrillaton and stroke: concepts and controversies. Stroke. 2001; 32: 803-808. Go to original source... Go to PubMed...
  18. Aschenberg W, Schluter M, Kremer P et al. Transesophageal twodimensional echocardiography for the detection of lest atrila appendage thrombus. J Am Coll Cariol. 1986; 7: 163-166. Go to original source... Go to PubMed...
  19. Masawa N, Yoshida Y, Yamada T et al. Diagnosis of cardiac thrombosis in patients with atrial fibrillation in the absence off macroscopically visible thrombi. Virchows Arch A Pathol Anat Histopathol. 1993; 422: 67-71. Go to original source... Go to PubMed...
  20. Shirani J, Alaeddini J. Structural remodelling of the left atrial appendage in patients with chronic non-valvular atrial fibrillation: Implication for thrombus formation, systemic embolism, and assessment by transesophahela echocardiography. Cardiac Pathol. 2000; 9: 95-101. Go to original source... Go to PubMed...
  21. Fukuchi M, Watanabe J, Kumagai K et al. Increased von Willebrand factor for thrombogenesis in overloaded human atrial appendage. J Am Coll Cardiol. 2001; 37: 1436-1442. Go to original source... Go to PubMed...
  22. Kumagai K, Fukunami M, Ohmori M et al. Increased intracardiovascular clotting in patients with chronic atrial fibrillation. J Am Coll Cardiol. 1990; 16: 377-380. Go to original source... Go to PubMed...
  23. Lip GY, Lowe GD, Rumley A et al. Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment. Br Heart J. 73: 527-533. Go to PubMed...
  24. Lip GY, Rumley A, Dunn FG et al. Plasmas fibrinogen and fibrin D-dimer in patients with atrial fibrillation: effect of cardioversion to sinus rhythm. Int J Cardiol. 1995; 51: 245-251. Go to original source... Go to PubMed...
  25. Heppell RM, Berkin KE, McLenachan JM et al. Haemostatic and haemodynamic abnormalities associated with left atrial thrombosis in non-rheumatic atrial fibrillation. Heart. 1997; 77: 407-411. Go to original source... Go to PubMed...
  26. Conway DS, Pearce LA, Chin BSP et al. Plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 1321 patients with non-valvular atrial fibrillation: relationship to stroke risk factors. Circulation. 2002; 106: 1962-1967. Go to original source... Go to PubMed...
  27. Conway DS, Pearce LA, Chin BSP et al. High plasma von Willebrand factor levels predict future stroke, myocardial infarction and vascular death in 994 patients with atrial fibrillation. Eur Heart J. 2002; 23 (suppl): 239.
  28. Hart RG, Pearce LA, McBride R et al. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigation. Stroke. 1999; 30: 1233-1239. Go to original source... Go to PubMed...
  29. Hart RG, Pearce LA, Miller VT et al. Cardioembolic vs noncardioembolic strokes in atrila fibrillation: frequency and effect of antithormbotic agents in the stroke prevention in atrial fibrillation studies. Cerebrovascular Dis. 2000; 10: 39-43. Go to original source... Go to PubMed...
  30. Blackshear JL, Pearce LA, Hart RG et al. Aoritc plaque in atrial fibrillation: prevalence, predictors and tromboembolic implications. Stroke. 1999; 30: 834-840. Go to original source... Go to PubMed...
  31. Fang MC, Singer DE, Chang Y et al. Gender differences on the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the Anticoagulation and Risk factors In Atrial fibrillation (ATRIA) study. Circulation. 2005; 112: 1687-1691. Go to original source... Go to PubMed...
  32. Yohida M, Nakamura Y, Higashikawa M et al. Predictors of ischemic stroke in non-rheumatic atrial fibrillation. Int J Cardiol. 1996; 56: 61-70. Go to original source... Go to PubMed...
  33. Brian F, Walraven C, Pearce L et al. Selecting patients with atial fibrillation for anticoagulation. Stroke risk stratification in patients taking aspirin. Circulation. 2004; 110: 2287-2292. Go to original source... Go to PubMed...
  34. Gabe BF, Waterman AD, Shanon W et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial fibrillation. JAMA. 2001; 285: 2864-2870. Go to original source... Go to PubMed...
  35. Rowan SB, Bailey DN, Bublitz CE et al. Trends in Anticogulation for Atrial Fibrilltion in the U. S. J Am Coll Cardiol. 2007; 49: 1561-1565. Go to original source... Go to PubMed...
  36. Murray RD, Deitcher SR, Shah A et al. Potential clinical efficacy and cost benefit of a transesophageal echocardiography-guided low-molecular-weight heparin (enoxaparin) approach to antithrombotic therapy in patients undergoing immediate cardioversion from atrial fibrillation. J Am Soc Echocardiogr. 2001; 14: 200-208. Go to original source... Go to PubMed...
  37. Stellbrink C, Nixdorff U, Hofmann T et al. Safety and efficacy of enoxaparin compared with unfractionted heparin and oral anticoagulatnts for prevention of thormboembolic complications in cardio version of non valvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial. Circulation. 2004; 109: 997-1003. Go to original source... Go to PubMed...
  38. Stein PD, Alpter JS, Bussey HI et al. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest. 2001; 119: 220S-227S. Go to original source... Go to PubMed...
  39. Bernhardt P, Schmidt H, Hammerstingl C et al. Atrial thrombi- a prospective follow-up study over 3 years with transesophageal echocardiography and cranial magnetic resonance imaging. Echocardiography. 2006; 23: 388-394. Go to original source... Go to PubMed...
  40. Leung DY, Davidson MP, Cranney BG et al. Thromboembolic risks of left atrial thrombus detected by transesophageal echocardiogram. Am J Cardiol. 1997; 76: 626-629. Go to original source... Go to PubMed...
  41. Tsunenori S, Kochi T, Daisuke U et al. Histopathological evaluation of left atrial appendage thrombogenesis removed during surgery for atrial fibrillation. AHJ. 2007; 153: 704-711. Go to original source... Go to PubMed...
  42. Jessurum ER, van Hemel NM, Defauw JJ et al. A randomized study of combining maze for atrial fibrillation with mitral valve surgery. J Cardiovascular Surg. 2003; 44: 9-18.
  43. Natale A, Raviele A, Arentz TH et al. Venice chart international consensus document on atrial fibrillation ablation. J Cardiovas Electrophysiol. 2007; 18: 560-580. Go to original source... Go to PubMed...




Interventional Cardiology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.